Biosimilar allergy drug trial halted after just one volunteer
NCT ID NCT04361812
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial aimed to see if a new biosimilar drug called HS632 works like the approved allergy drug Omalizumab (Xolair) in healthy volunteers. The study planned to compare how the body absorbs and handles each drug after a single injection. However, the trial was terminated early with only one participant enrolled, so no meaningful results were obtained.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HS632 (a biosimilar of omalizumab)
- What this could lead to
- If successful, this could support the development of a more affordable version of omalizumab for allergic conditions.
- What could go wrong
- This was a very early Phase 1 study in only healthy people, not patients. It was terminated early with just one participant, so no conclusions can be drawn.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SIMILARITY OF PHARMACOKINETICS AND SAFETY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Anhui Peng
Shanghai, Shanghai Municipality, 200040, China